Clinical Trials
15 trialsNCT05104983 2026-01-22
TSC-STEPS
Children's Hospital Medical Center, Cincinnati
Phase 2 Recruiting
NCT03363763 2025-12-01
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
Aucta Pharmaceuticals, Inc
Phase 2 Terminated
NCT04595513 2024-05-16
STOP2
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT04987463 2024-02-08
ViRap
Children's Memorial Health Institute, Poland
Phase 2/3 Unknown
NCT03826628 2023-09-08
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Dermatology Specialties Limited Partnership
Phase 2/3 Completed
NCT05534672 2023-08-08
RaRE-TS
Children's Memorial Health Institute, Poland
Phase 3 Recruiting
NCT00126672 2022-04-25
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01929642 2021-03-29
RAPT
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT01526356 2020-10-26
Treatment
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02061397 2020-08-25
SOS
University of Pennsylvania
Phase 1/2 Completed
NCT03140449 2017-05-04
Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis
National Taiwan University Hospital
Phase 3 Completed
NCT01853423 2016-08-19
Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
Le Bonheur Children's Hospital
Phase 1 Completed
NCT01031901 2012-02-27
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
The University of Texas Health Science Center, Houston
Phase 1 Completed
NCT00490789 2008-04-30
TESSTAL
Cardiff University
Phase 2 Unknown
NCT00457808 2007-04-09
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
Children's Hospital Medical Center, Cincinnati
Phase 2 Completed